BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value

$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

KPIs

Operating metrics that drive BeOne Medicines's business · fiscal year ends Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30

Consolidated Total Revenue ($M)($M)6	1,705	1,513	1,498	1,412	1,315	1,117	1,128	1,002	929	752	634	781
Net Product Revenue ($M)($M)4	1,680	1,487	1,476	1,395	1,302	1,109	1,118	994	921	747	631	595
Product Revenue — United States ($M)($M)	899	766	850	743	685	563	616	504	479	352	313	270
Product Revenue — China ($M)($M)	500	465	399	435	429	396	358	370	347	316	267	285
Product Revenue — Europe ($M)($M)	208	191	174	167	152	117	114	97.5	81.4	66.8	45.7	30.7
Product Revenue — Rest of World ($M)($M)	73.1	65.2	53.4	51	35.6	31.9	30.7	21.9	13.3	13	4.30	9.60
Collaboration & Other Revenue ($M)($M)6	25.3	26.1	21.7	17.3	13.2	8.80	9.80	8.20	8	4.70	3.90	186
Collaboration & Other Revenue — United States ($M)($M)	15.6	16.6	14	12.2	9	3.90	3.20	1.70	2.10	0	0	128
Collaboration & Other Revenue — China ($M)($M)	6.30	6.80	7.70	5.10	4.10	3.20	5.20	5.70	5	4.70	3.30	3
Collaboration & Other Revenue — Europe ($M)($M)	0.30	2.70	0	0	0.10	1.70	1.40	0.70	1	0	3	54.9
Collaboration R&D Service Revenue ($M, FY16–FY22)($M)												59
Collaboration Right-to-Access IP Revenue ($M, FY19–FY22)($M)												52
Other Collaboration Revenue ($M, FY17–FY22)($M)												3
Total Revenue — United States ($M)($M)	914	782	864	755	694	567	619	506	481	352	313	398
Total Revenue — China ($M)($M)	506	472	407	440	433	400	363	376	352	320	271	288
Total Revenue — Europe ($M)($M)	209	194	174	167	152	119	115	98.3	82.4	66.9	48.7	85.6
Total Revenue — Rest of World ($M)($M)	76.1	65.2	53.4	51	35.6	31.9	30.7	21.9	13.3	13	1.90	9.60

BRUKINSA (zanubrutinib, BTKi) — Global Net Product Revenue ($M)($M)4	1,248	1,095	1,146	1,041	950	792	828	690	637	489	413	358
BRUKINSA — Global Revenue Growth YoY (%)(%)	31.4%	38.3%		50.8%	49.0%	62.1%		93.0%	106.8%	131.1%		130.0%
BRUKINSA — United States Net Product Revenue ($M)($M)1	893	761	845	739	684	563	616	504	479	352	313	270
BRUKINSA — United States Revenue Growth YoY (%)(%)	30.5%	35.1%	37.0%	46.6%	42.6%	60.2%	97.0%	86.5%	114.4%	153.3%		149.8%
BRUKINSA — Europe Net Product Revenue ($M)($M)1	196	182	167	163	151	116	113	97.3	81.4	66.8		30.7
BRUKINSA — Europe Revenue Growth YoY (%)(%)	30.0%	57.4%		67.8%	84.9%	73.4%		217.2%	209.2%	242.8%
BRUKINSA — China Net Product Revenue ($M)($M)1	97.2	94	87.4	92.4	83.2	81.1		67.8	63.6	57.4	49.8	47.4
BRUKINSA — China Revenue Growth YoY (%)(%)	16.7%	15.9%		36.2%	30.8%	41.3%		43.0%	31.2%	19.4%		20.8%
TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M)($M)1	229	206	182	191	194	171	154	163	158	145	128	144
TEVIMBRA — Global Revenue Growth YoY (%)(%)	18.1%	20.5%	18.0%	16.7%	22.2%	17.8%	20.0%	12.8%	5.9%	26.4%		12.6%
Amgen In-Licensed Products — Total Net Product Revenue ($M)($M)4	157	142	112	133	126	114		102	90.1	71.9		50.4
Amgen In-Licensed Products — Revenue Growth YoY (%)(%)	24.5%	25.0%	11.0%	31.0%	40.2%	58.7%		101.5%	81.7%
XGEVA (denosumab, RANKL Inhibitor — Amgen In-Licensed) ($M)($M)	105	89.9	70	84.2	81.3	70.4	62.5	63.5	55	43.4	24.2	24.5
BLINCYTO (blinatumomab, CD19×CD3 BiTE — Amgen In-Licensed) ($M)($M)	36.5	34	24.2	30.5	25.6	23.9	20.6	20.2	19.1	14.4	13.9	14.9
KYPROLIS (carfilzomib, Proteasome Inhibitor — Amgen In-Licensed) ($M)($M)	15.2	17	17.5	18.4	19.4	19.7	18.1	18	15.9	14.1	12.7	11.1
POBEVCY (bevacizumab biosimilar — Bio-Thera In-Licensed) ($M)($M)	9.60	12.1	11.9	10.5	11.2	13.7	13.1	12.2	11.6	16.6	14.7	14.1
Other Marketed & Partnered Products — Net Product Revenue ($M)($M)3	37.8	33.2	24.5	20.1	21.1	17.9	21.8	26	23.6	24.6	84	13.7
PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY20–FY23)($M)											1.10	1.90
REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24)($M)							3.60	11.1	9.10	12.2	16.1	15
VIDAZA (azacitidine — BMS/Celgene China Partnered) ($M, FY18–FY23)($M)											2.50	4.30

Total Research & Development Expense ($M)($M)4	612	541	615	524	525	482	542	496	455	461	494	453
Internal R&D Expense ($M)($M)	365	354	361	320	315	291	315	325	296	289	281	296
Total External R&D Expense ($M)($M)3	248	188	255	204	210	191	227	171	159	171	213	157
External Cost of Development Programs ($M)($M)	194	158	228	174	183	170	143	149	125	123	167	126
Amgen Co-Development Expense Charged to R&D ($M)($M)	30.3	29.4	26.9	30.1	26.4	20.7	22.2	17	22.5	13.5	13.7	16.3
Upfront License & Development Milestone Fees ($M)($M)3	23.3	0.50	0	0.20	20.5	0	62.5	5	11.5	35	37.6	24.4
Upfront License Payments Expensed to R&D ($M)($M)	20	0.50	0	0.20	0.50	0	60	0	0	0	31.8	15
Development Milestone Payments Expensed to R&D ($M)($M)	3.30				0					35
Cash Payments for Acquired In-Process R&D ($M)($M)	20.5	0	0	0.70	0	60	0	0	0	31.8	0	15
Accrued External R&D Activities Liability ($M)($M)	167	199	157	125	106	91.6	154	112	133	99	163	92.7
Prepaid R&D Costs ($M)($M)	48.2	36.1	52.6	70	76.2	44.1	64.3	60.2	68.2	66.8	60.5	73
Amgen Collaboration — Total R&D Financing Commitment Expense ($M)($M)4	59.8	58	53.2	59.3	52.2	40.5	43.8	33.6	44.4	26.6	30.4	32.2
Amgen R&D Financing Liability Amortization (Offset to R&D Expense) ($M)($M)	29.5	28.6	26.2	29.3	25.8	19.8	21.6	16.6	21.9	13.1	16.7	15.9
Amgen R&D Cost-Share Liability — Total Carrying Value ($M)($M)1	6.20	35.7	64.3	90.6	120	146	165	187	204	226	239	255
Amgen R&D Cost-Share Liability — Current Portion ($M)($M)	6.20	35.7	64.3	90.6	109	111	111	104	84.6	82	68	63.6
Amgen Commercial Inventory Purchases (Related-Party) ($M)($M)	132	124	43.6	84.2	73.3	62.7	94.7	43.1	47.6	62.2	50.7	18.8
Amgen Remaining Co-Development Funding Commitment ($M)($M)	12.5	72.3	130	184	243	295	335	379	413	457	484	518
Profit-Share & Collaboration Reimbursement Expense — Total Net ($M)($M)3	-15.6	-15.4	17.6	15	-17.1	-17	-82.8	11.6	11.9	10.3	-88.8	11.1
Reimbursement Expense — Cost of Sales ($M)($M)	12.7	11.2	-9	-10	9.50	7.50	-8.70	-10.3	-9.60	-8.60	-4	-3.20
Reimbursement Expense — Research & Development ($M)($M)	-1.10	-0.20	0.60	0.40	-1.60	-0.50	1	0.30	0.40	0.70	0.10	-0.40
Reimbursement Expense — Selling, General & Administrative ($M)($M)	-27.1	-26.4	25.9	24.6	-25	-23.9	22.8	21.6	21.1	18.1	16.9	14.7
Novartis Collaboration Revenue Recognized ($M)($M)	25.3	26.1	21.7	17.3	13.2	8.80	9.80	8.20	8	4.70	3.90	186

Gross Product Revenue Before Rebates & Returns ($M)($M)1	2,206	1,894		1,771	1,658	1,400		1,246	1,167	945	811	732
Sales Rebates, Returns & Discounts Deducted from Gross Revenue ($M)($M)	526	406		376	356	292		252	246	198	180	136
Accrued Sales Rebates & Returns Reserve — Ending Balance ($M)($M)2	486	440	399	383	297	260	236	214	173	186	140	112
Provision for Sales Rebates & Returns Charged to Revenue ($M)($M)	526	406	426	376	356	292	312	252	246	198	180	136
Payments & Credits Applied Against Sales Rebates & Returns Reserve ($M)($M)	479	382	382	292	301	283	274	219	245	153	131	110
Accrued Commercial Activities Liability ($M)($M)	132	123	119	125	99.8	76.8	77.5	80.8	70.6	74.8	87.6	60.7

GAAP Gross Margin (% of Global Product Sales)(%)3	90.0%	89.0%	90.4%	85.9%	87.4%	85.1%	85.6%	83.0%	85.0%	83.0%	83.2%	83.8%
Non-GAAP Adjusted Gross Margin (% of Global Product Sales, FY23–FY25)(%)			90.7%	86.3%	88.1%	85.5%	87.4%	84.9%	85.4%	83.7%	83.7%
GAAP Cost of Sales — Product ($M)($M)	175	167	142	197	165	165	161	171	138	125	106	96.3
Non-GAAP Adjusted Cost of Sales — Product ($M)($M)	167	161	137	191	155	161	141	150	134	121	103	93.0
Non-GAAP Adjusted Operating Expenses ($M)($M)3	1,035	938	1,016	880	886	817	908	786	746	778	799	705
Non-GAAP Adjusted Research & Development Expense ($M)($M)	534	466	545	446	444	421	475	406	383	405	437	396
Non-GAAP Adjusted Selling, General & Administrative Expense ($M)($M)	501	472	471	434	442	396	433	381	364	372	361	308
GAAP SG&A Expense as % of Product Sales (%)(%)	35.0%	37.0%	38.0%	38.0%	41.0%	41.0%	45.0%	46.0%	48.0%	57.0%	66.0%	61.0%
Non-GAAP Adjusted Operating Income (Loss) ($M)($M)2	503	414	344	341	275	139	78.6	65.6	48.5	-147	-267	-16.3
Non-GAAP Adjusted Net Income (Loss) ($M)($M)	444	375	225	304	253	136	16.1	51.6	23.3	-146
Non-GAAP Free Cash Flow ($M)($M)	435	161	380	354	220	-12.3	-17.3	54.7	-206
GAAP Diluted Earnings (Loss) per ADS ($/ADS, 1 ADS = 13 Ordinary Shares)($)7	2.05	1.96		1.09	0.84	0.01		-1.15	-1.15	-2.41		2.01
GAAP Basic Earnings (Loss) per ADS ($/ADS)($)	2.12	2.05		1.13	0.87	0.01		-1.15	-1.15	-2.41		2.06
Non-GAAP Adjusted Diluted Earnings (Loss) per ADS ($/ADS)($)	3.84	3.24	1.95	2.65	2.25	1.22	0.15	0.48	0.22	-1.40
Non-GAAP Adjusted Basic Earnings (Loss) per ADS ($/ADS)($)	3.98	3.38	2.03	2.76	2.33	1.27	0.15	0.49	0.22	-1.40
Non-GAAP Adjusted Diluted Earnings (Loss) per Ordinary Share ($/sh)($)	0.30	0.25	0.15	0.20	0.17	0.09	0.01	0.04	0.02	-0.11
Non-GAAP Adjusted Basic Earnings (Loss) per Ordinary Share ($/sh)($)	0.31	0.26	0.16	0.21	0.18	0.10	0.01	0.04	0.02	-0.11
Weighted-Average Diluted ADSs Outstanding (M ADSs)(M)	116	116		115	113	111		106	105	104		107
Weighted-Average Basic ADSs Outstanding (M ADSs)(M)	112	111		110	108	107		106	105	104		105

Total Net Inventories ($M)($M)3	733	682	608	532	503	495	495	432	443	447	416	317
Raw Materials Inventory ($M)($M)	267	274	236	179	181	177	171	147	144	158	149	94
Work in Process (WIP) Inventory ($M)($M)	114	109	123	101	98.9	67	60.1	62	59.5	49.4	39.1	40
Finished Goods Inventory ($M)($M)	351	298	249	252	223	250	264	222	240	240	228	183
Property, Plant & Equipment, Net ($M)($M)3	1,643	1,641	1,642	1,628	1,616	1,599	1,578	1,563	1,517	1,418	1,324	1,178
Property, Plant & Equipment, Gross ($M)($M)6	2,110	2,077	2,043	1,985	1,715	1,437	1,324	1,304	942	900	833	768
PP&E Gross — Buildings ($M)($M)	1,205	1,197	1,188	1,168	933	704	608	608	305	281	232	215
PP&E Gross — Manufacturing Equipment ($M)($M)	289	283	274	267	259	252	244	249	227	217	187	173
PP&E Gross — Laboratory Equipment ($M)($M)	329	319	310	290	270	250	241	236	217	211	205	187
PP&E Gross — Leasehold Improvements ($M)($M)	79.5	77.2	76.6	73.8	74.5	63.1	64.7	60.7	60.4	59.4	60.1	53.1
PP&E Gross — Software & Computer Equipment ($M)($M)	136	130	124	115	107	102	100	83.8	67.7	66.7	83.3	74.8
PP&E Gross — Land & Land Use Rights ($M)($M)	71.4	71.4	71.4	71.4	71.4	65.5	65.5	65.5	65.5	65.5	65.5	65.5
Accumulated Depreciation — PP&E ($M)($M)	620	574	529	486	453	428	399	366	289	265	249	221
Capital Expenditures Incurred but Not Yet Paid ($M)($M)	5.90	43.2	5.20	-5.90	-2.10	60	-5	-40.2	15.1	101	-15.8	12.2
Finite-Lived Intangible Assets, Net ($M)($M)9	61	61.7	62.7	63.6	64.9	50.1	51.1	53.9	53.7	55.2	57.1	53.7
Finite-Lived Intangible Assets, Gross ($M)($M)2	88.5	87.4	86.5	85.6	85.3	72.2	71.9	73.8	72.1	72.4	73.3	66.7
Gross Intangibles — Developed Technology Rights ($M)($M)	79.5	78.4	77.5	76.6	76.3	63.2	62.9	64.8	63.1	63.4	64.3	58.4
Gross Intangibles — Licensing Agreements ($M)($M)	9	9	9	9	9	9	9	9	9	9	9	0.80
Accumulated Amortization — Finite-Lived Intangible Assets ($M)($M)2	27.5	25.7	23.8	22	20.4	22	20.8	19.9	18.4	17.2	16.1	13.1
Accumulated Amortization — Developed Technology Rights ($M)($M)	19	17.2	15.3	13.6	11.9	13.6	12.4	11.5	10.1	8.90	7.80	6.60
Accumulated Amortization — Licensing Agreements ($M)($M)	8.50	8.50	8.50	8.50	8.40	8.40	8.40	8.40	8.30	8.30	8.30	0.80
Net Intangibles — Developed Technology Rights ($M)($M)	60.5	61.2	62.2	63	64.3	49.6	50.5	53.4	53	54.5	56.5	51.8
Net Intangibles — Licensing Agreements ($M)($M)	0.50	0.50	0.50	0.50	0.60	0.60	0.60	0.60	0.70	0.70	0.70	0
Amortization of Intangible Assets — Total ($M)($M)2	1.60	1.80	1.60	1.60	5.80	1.20	1.20	1.30	1.20	1.20	3	2.30
Amortization of Intangible Assets — Cost of Sales ($M)($M)	1.60	1.70	1.50	1.50	5.80	1.20	1.20	1.20	1.20	1.20	1.10	1
Amortization of Intangible Assets — Operating Expenses ($M)($M)	0	0	0	0	0	0	0	0.10	0	0	1.80	1.30
Estimated Intangible Amortization — Next 12 Months / Year 1 ($M)($M)	6.50	8.10	6.30	8.30	6.20	4.80	4.80	4.90	4.80	4.80	5	6.20
Estimated Intangible Amortization — Year 2 ($M)($M)	6.50	8.10	6.30	8.30	6.20	4.80	4.80	4.90	4.80	4.80	5	6.20
Estimated Intangible Amortization — Year 3 ($M)($M)	6.50	8.10	6.30	8.30	6.20	4.80	4.80	4.90	4.80	4.80	5	6.20
Estimated Intangible Amortization — Year 4 ($M)($M)	6.50	8.10	6.30	8.30	6.20	4.80	4.80	4.90	4.80	4.80	4.80	6.20
Operating Lease Right-of-Use (ROU) Assets ($M)($M)2	146	146	148	140	146	146	139	101	104	87.8	95.2	98.7
Operating Lease Liabilities — Current ($M)($M)	21.9	20.6	20.7	15.7	17.2	18.3	17.6	17.7	17.7	19.4	21.9	23.2
Operating Lease Liabilities — Noncurrent ($M)($M)	48.2	49.7	52.9	51.4	53.9	54.9	44.3	32.5	35.4	17.7	22.2	25.5

Current Portion of Long-Term Debt & Bank Loans ($M)($M)2	191	116	57.3		808	764	852	864	852	827	688	329
Noncurrent Long-Term Debt & Bank Loans ($M)($M)	882	963	962		146	160	167	188	185	199	198	203
Noncurrent Portion of RMB-Denominated Bank Loans (RMB M)(M)							1,215	1,316	1,347	1,437	1,403	1,478
Unrecognized Tax Benefits (UTB) — Ending Balance ($M)($M)3	26.1	28.5	27.8	22	21.5	17.6	17.2	17.6	15.8	14.9	14.3	13.9
Deferred Income Tax Liabilities, Net ($M)($M)	57.4	55.9	53.2	47.1	44.1	43.1	42	15.9	15.9	16.4	16.5	16.4
Income Taxes Paid, Net ($M)($M)	70.6	-2.70	20.7	2.90	67.7	9.30	14.7	9.10	43.1	2.50	13.5	10
Noncurrent Value-Added Tax (VAT) Receivable ($M)($M)	3.80	3.60	3.50	3.30	3.10	3.10	2.90	2.80	2.60	2.80	2.50	2
Total Share-Based Compensation Expense ($M)($M)2	138	123	124	141	151	95.5	108	115	131	88.7	92.8	96.1
Share-Based Compensation — Research & Development ($M)($M)	58.5	53.9	52.4	58.8	64.4	41.8	45	47.7	55.4	38	39.4	44.1
Share-Based Compensation — Selling, General & Administrative ($M)($M)	78.9	69.5	71	82	86.2	53.7	62.8	66.9	75.3	50.7	53.3	52

Global Full-Time Employees (Form 10-K / 10-Q & ESG Report)	12,000	12,000	12,000	12,000	11,000	11,000	11,000			10,000	10,000	10,000

Income Statement — Total revenue ($M)($M)13	1,705	1,513	1,498	1,412	1,315	1,117	1,128	1,002	929	752	634	781
Cost of sales — product ($M)($M)	175	167	142	197	165	165	161	171	138	125	106	96.3
Gross profit ($M)($M)	1,531	1,346	1,356	1,216	1,151	952	967	831	791	627	529	685
Research and development expense ($M)($M)	612	541	615	524	525	482	542	496	455	461	494	453
Selling, general and administrative expense ($M)($M)	593	555	555	529	538	459	505	455	444	427	418	366
Total operating expenses ($M)($M)	1,206	1,096	1,171	1,053	1,063	941	1,047	951	898	888	912	819
Income (loss) from operations ($M)($M)	325	250	185	163	87.9	11.1	-79.4	-120	-107	-261	-384	-134
Income (loss) before income taxes ($M)($M)	313	259	149	147	99.5	20.9	-85.4	-98.3	-106	-243	-351	229
Income tax expense ($M)($M)	75.5	31.9	82.7	22.3	5.20	19.6	66.5	23	14.5	7.70	16.8	13.9
Net income (loss) ($M)($M)	237	227	66.5	125	94.3	1.30	-152	-121	-120	-251	-368	215
Earnings (loss) per ordinary share — Basic ($/sh)($)	0.16	0.16		0.09	0.07	0		-0.09	-0.09	-0.19		0.16
Earnings (loss) per ordinary share — Diluted ($/sh)($)	0.16	0.15		0.08	0.06	0		-0.09	-0.09	-0.19		0.15
Weighted-average basic ordinary shares outstanding (M)(M)	1,451	1,443		1,433	1,408	1,390		1,377	1,361	1,356		1,361
Weighted-average diluted ordinary shares outstanding (M)(M)	1,505	1,505		1,489	1,463	1,445		1,377	1,361	1,356		1,390
Balance Sheet — Total assets ($M)($M)12	9,176	8,554	8,189	7,633	6,298	5,842	5,921	5,831	5,712	5,668	5,805	5,525
Cash and cash equivalents ($M)($M)	5,098	4,792	4,548	4,037	2,756	2,516	2,639	2,702	2,593	2,793	3,172	3,067
Accounts receivable, net ($M)($M)	1,056	938	865	863	771	717	676	569	529	435	358	309
Inventories, net ($M)($M)	733	682	608	532	503	495	495	432	443	447	416	317
Total current assets ($M)($M)	7,216	6,601	6,234	5,665	4,310	3,897	3,992	3,912	3,839	3,908	4,203	4,054
Property, plant and equipment, net ($M)($M)	1,643	1,641	1,642	1,628	1,616	1,599	1,578	1,563	1,517	1,418	1,324	1,178
Intangible assets, net ($M)($M)	61	61.7	62.7	63.6	64.9	50.1	51.1	53.9	53.7	55.2	57.1	53.7
Accounts payable ($M)($M)	470	424	479	384	361	365	405	308	333	357	315	342
Total current liabilities ($M)($M)	2,119	1,812	1,829	2,368	2,210	1,984	2,215	2,025	1,939	1,882	1,810	1,283
Long-term bank loans ($M)($M)	882	963	962		146	160	167	188	185	199	198	203
Total liabilities ($M)($M)	4,002	3,793	3,827	3,503	2,528	2,342	2,589	2,395	2,346	2,307	2,268	1,762
Accumulated deficit ($M)($M)	-7,856	-8,093	-8,320	-8,386	-8,511	-8,606	-8,607	-8,455	-8,334	-8,213	-7,962	-7,595
Total shareholders' equity ($M)($M)	5,174	4,760	4,361	4,129	3,771	3,500	3,332	3,436	3,366	3,360	3,537	3,763
Cash Flow Statement — Operating cash flow ($M)($M)4	463	201	417	403	264	44.1	75.2	188	-95.6	-309	-222	-78.1
Capital expenditures ($M)($M)	27.5	40.8	37.5	48.1	43.8	56.4	92.5	134	110	157	157	158
Share-based compensation expense ($M)($M)	138	123	124	141	151	95.5	108	115	131	88.7	92.9	96.1
Investing cash flow ($M)($M)	-49.4	-45.5	-38.3	-49.3	-66.6	-122	-93.6	-134	-111	-210	-62.6	-186
Financing cash flow ($M)($M)	-6.10	68.6	96.9	961	35	-33.8	-4.50	12.7	23	162	347	-76.8

2 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Fiscal calendar & corporate identity: BeOne Medicines Ltd. (formerly BeiGene, Ltd.; redomiciled to Basel, Switzerland and renamed in May 2025; NASDAQ: ONC, HKEX: 06160, SSE STAR: 688235; 1 ADS = 13 ordinary shares) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026; latest HKEX monthly return Sep 2026). BeOne operates as a single global oncology operating segment.
Core commercial, STAR Market & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenue ($1,705.1M in Q2 2026 / $5,343.0M in FY25: Net Product Revenue $1,679.8M in Q2 2026 / $5,282.1M in FY25 and Collaboration/Other Revenue $25.3M in Q2 2026 / $61.0M in FY25) disaggregated across United States ($919.6M in Q2 2026 / $2,866.8M in FY25), China ($451.7M in Q2 2026 / $1,572.6M in FY25), Europe ($260.7M in Q2 2026 / $621.8M in FY25), and Rest of World ($73.1M in Q2 2026 / $281.8M in FY25); (2) Commercial Oncology Portfolio by medicine & region: BRUKINSA ($1,247.6M in Q2 2026 / $3,928.5M in FY25, +31.4% YoY in Q2 2026: U.S. $892.5M / +30.5%, Europe $206.4M / +37.3%, China $106.0M / +27.5%, RoW $42.7M / +30.6%), TEVIMBRA ($228.5M in Q2 2026 / $737.3M in FY25, +18.1% YoY in Q2 2026), Amgen in-licensed portfolio ($141.0M in Q2 2026 / $486.2M in FY25: XGEVA $104.5M, BLINCYTO $36.5M, KYPROLIS $17.8M in Q2 2026), POBEVCY ($14.6M in Q2 2026 / $62.0M in FY25), and legacy BMS/Celgene partnered brands; (3) SSE STAR Market (688235.SS) exclusive operational disclosures: physical production/purchase volume (6.27M vials in FY25), physical sales volume (6.00M vials in FY25), ending inventory (2.91M vials in FY25) of key self-developed/in-licensed products, and regional product gross margin split between Ex-China (94.75% in FY25) and Mainland China (70.11% in FY25); (4) R&D Expense ($562.1M in Q2 2026 / $2,145.9M in FY25) split into Internal R&D ($329.8M in Q2 2026 / $1,254.0M in FY25) and External R&D ($232.2M in Q2 2026 / $891.9M in FY25), 9-year molecule-level external R&D allocation from STAR Market reports (BRUKINSA, TEVIMBRA, Sonrotoclax/BEQALZI, BGB-16673/Tacabrutideg, BGB-43395), and Amgen/Novartis collaboration accounting; (5) Gross-to-Net (GTN) sales rebates deducted ($525.8M in Q2 2026) and Accrued Sales Rebates & Returns Reserve rollforward ($485.9M at Q2 2026); and (6) GAAP vs. Non-GAAP Gross Margin (90.0% GAAP in Q2 2026; 87.3% GAAP / 87.8% Adjusted in FY25), SG&A as % of product sales (35% in Q2 2026 vs. 80% in Q1 2023), Adjusted Operating Income ($517.8M in Q2 2026 / $1,100.0M in FY25), Adjusted Net Income ($446.1M in Q2 2026 / $917.6M in FY25), Non-GAAP Free Cash Flow ($429.9M in Q2 2026 / $941.7M in FY25), and GAAP/Adjusted EPS per ADS.
Groups 7–11 cover: (7) 74 consecutive months of HKEX Form FF301 Monthly Returns (2020-08..2026-09): HKEX ordinary shares (1,427.23M at Sep 2026), SSE STAR RMB shares (115.06M at Sep 2026), 2016 Plan options outstanding (51.32M at Sep 2026), monthly grants/cancellations/exercises, BG NC 2, Ltd. award pool utilization (74.69M shares issued through Sep 2026), and monthly cash proceeds from option exercises ($7.99M in Sep 2026); (8) Manufacturing inventory by stage ($766.3M net at Q2 2026), PP&E by category ($1,613.5M net at Q2 2026), finite-lived intangibles & 5-year amortization schedule, and operating leases; (9) USD & RMB debt facilities, Unrecognized Tax Benefits rollforward ($65.4M at Q2 2026), Share-Based Compensation ($137.5M in Q2 2026), Issued U.S. (88) & China (77) patents at FY25, and DEF 14A CEO Pay Ratio (171:1 in FY25) & Pay vs. Performance; (10) Global Workforce (12,200 employees at Q2 2026 / 11,760 at FY25 across 5 regions; 2,520 new hires and 10.6% voluntary turnover in FY25), safety (0.14 TRIR / 0.08 LTIR in FY25), and Scope 1/2/3 GHG emissions, energy, water, and waste (FY19–FY25); and (11) FRED pharmaceutical benchmarks and DB financial statements.
Swiss Standalone Statutory Financial Statements (prepared in CHF under the Swiss Code of Obligations for parent holding company BeOne Medicines Ltd., 2025) report CHF 490.2M in dividend income from subsidiaries and no external product revenue, and are in a different currency (CHF vs. USD) and accounting basis from U.S. GAAP consolidated statements; therefore no Consolidated − Standalone subtraction is performed. The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Data updated 2026-10-29.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Consolidated Revenue by Type & Geographic Region ($M)

Consolidated Total Revenue ($M) ($M)46 periods

BeOne Medicines Ltd. (ONC) operating KPIs

KPIs

Every KPI on its own page

Consolidated Revenue by Type & Geographic Region ($M)

Commercial Oncology Portfolio — Revenue by Medicine & Region ($M, YoY %)

SSE STAR Market (688235.SS) Physical Volume (Vials) & Regional Gross Margin Breakdown

R&D Expense by Pipeline Molecule, Internal vs. External R&D & Collaborations ($M)

Gross-to-Net (GTN) Sales Rebates & Returns Rollforward ($M)

GAAP vs. Non-GAAP Profitability, Gross Margin & Per-ADS Metrics

HKEX Monthly Returns (Form FF301, 06160.HK) — Issued Shares & Option Activity (2020-08..2026-09)

Manufacturing Inventory by Stage, PP&E Breakdown, Intangibles & Leases ($M)

Debt Facilities ($M / RMB M), Taxes & UTB, Share-Based Comp, Patents & Governance

Global Workforce, Workplace Safety & Environmental Sustainability (10-K / ESG Reports)

Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)